Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic)

This page covers all Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Sodium channels (ropivacaine), mu-opioid receptors (morphine), alpha/beta-adrenergic receptors (epinephrine), cyclooxygenase 1 and 2 (ketorolac), GABA-B receptor, norepinephrine/serotonin transporters, NMDA receptor.

Targets

Sodium channels (ropivacaine), mu-opioid receptors (morphine), alpha/beta-adrenergic receptors (epinephrine), cyclooxygenase 1 and 2 (ketorolac) · GABA-B receptor, norepinephrine/serotonin transporters, NMDA receptor

Marketed (2)

• ropivacaine,morphine chloride,epinephrine,ketorolac · Jose Antonio Bernia Gil · Pain Management / Anesthesia
  This is a combination analgesic and anesthetic formulation that blocks nerve conduction (ropivacaine), activates opioid receptors (morphine), increases sympathetic tone (epinephrine), and inhibits prostaglandin synthesis (ketorolac) to provide multimodal pain relief and local anesthesia.
• multimodal:acetaminophen, gabapentin, ketamine, bupivacaine · University of Wisconsin, Madison · Pain Management
  This multimodal formulation combines four analgesic and anesthetic agents with distinct mechanisms to provide synergistic pain relief through multiple pathways.

Phase 3 pipeline (1)

• baclofen/amitriptyline/ketamine gel · Alliance for Clinical Trials in Oncology · Oncology (cancer-related neuropathic pain)
  This triple-agent topical gel combines a GABA-B agonist (baclofen), a tricyclic antidepressant (amitriptyline), and a dissociative anesthetic (ketamine) to provide multimodal analgesia for neuropathic pain.

Patent intelligence

• multimodal analgesic combination patent landscape — aggregated cliff calendar, attackable patents, originator estates